27 May 2020
New facilities available for Oncode researchers
We are pleased to announce that three facilities are now open to the whole Oncode research community. The goal of Oncode Institute is to translate the results of ground-breaking fundamental research into the clinic faster, in order to improve the chances of cancer patients. Instead of competition between scientists, Oncode encourages collaboration. Investing in facilities which can be used by all Oncode researchers, is one of the ways in which Oncode wants to contribute to breakthroughs in cancer research.
22 May 2020
In Memoriam: Professor Huib Ovaa
On the 19th of May 2020, our dear colleague Professor Dr. Huib Ovaa passed away from prostate cancer. In the past year, Huib has undergone a variety of treatments, and has done so with his usual optimism. He continued to work as much as possible and tried to keep the burden of his fight against cancer away from the people around him. Huib was 46 years of age.
15 May 2020
Oncode Institute is in Top 50 NPO/NGOs ranked by Nature Index
We are honoured to announce that Nature Index included Oncode Institute in its Top 50 NPO/NGO institutions in cancer research worldwide. Every year, Nature Index publishes its Cancer supplement, featuring a list of the most prominent institutes and academic, healthcare, NPO/NGO, government and corporate institutions working in cancer research.
14 May 2020
COVID-19: updates for the Oncode research community
As an Oncode researcher, you might have questions about how we are mitigating the impact of the current COVID-19 crisis on our programmes, projects and funding. We created a Q&A with the answers these questions and plan to update this Q&A regularly.
30 April 2020
Insight into Making Scientific Findings Publicly Available
Preprint servers like BioRxiv or MedRxiv are tools that can be combined with traditional peer reviewed journals to increase impact and visibility. Until 2019, only around 5% of publications by Oncode Investigators were shared via a preprint server before being published in a peer reviewed journal, whether OA or subscription. We spoke to Oncode Investigator Lude Franke (UMCG) about how publishing on BioRxiv strongly impacted his research.
In the spotlight
19 March 2020
Therapeutic vaccine boosts survival rate in cervical cancer patients
A therapeutic vaccine against HPV-16 (type 16 human papillomavirus) improves the survival rate in cervical cancer patients. A new study by Oncode Investigator Sjoerd van der Burg and others shows that this vaccine produces a more robust response if it is combined with chemotherapy. The results of this study have been published in the journal Science Translational Medicine.
24 April 2020
Dirk Pollet joins Oncode Oncology Bridge Fund as Entrepreneur in Residence
Following Dr. Markwin Velders and Dr. Allard Kaptein joining the Oncode Oncology Bridge Fund as Entrepreneurs in Residence this February, we are happy to announce that Dr. Dirk Pollet now joined the Oncode Oncology Bridge Fund’s team of experienced entrepreneurs.
27 March 2020
In memoriam: Anjo van Heijst
We received the sad news that Anjo van Heijst passed away on March 23. Anjo was one of the first patient representatives of Oncode’s Clinical Advisory Board. With her knowledge and enthusiasm, she contributed immensely to the development of our clinical programmes. She was also a driving force behind Werkgroep Darmkanker, a platform for patients with colon cancer and their loved ones.
20 March 2020
Two New Clinical Proof-of-Concept Projects Funded by Oncode Institute
Oncode Institute aims to link fundamental and clinical research to enable efficient translation of promising findings into novel diagnostic methods and clinical treatment strategies. We are pleased to announce that the 9th and 10th grant within the Clinical Proof of Concept programme have been awarded.
17 March 2020
The Oncode Compound Library: find new therapeutic applications that others missed
Oncode’s newly acquired Drug Repurposing Library is now available to all Oncode researchers, through the Drug Repurposing Programme. The library encompasses more than 6.000 unique compounds in different stages of clinical development. Each of them has extensively curated annotations, including details about commercial sources. Besides access to the library, Oncode will provide the technical infrastructure and expertise needed to perform complex compound screens.
Scroll for more